Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9\*\[^{f}g\]^1

Received for publication, November 1, 2011, and in revised form, January 23, 2012. Published, JBC Papers in Press, January 31, 2012, DOI 10.1074/jbc.M111.319764

Javier Chaparro-Riggers\[^{f1}\], Hong Liang\[^{f1}\], Rachel M. DeVay\[^{f}\], Lanfang Bai\[^{f}\], Janette E. Sutton\[^{f}\], Wei Chen\[^{f}\], Tao Geng\[^{f}\], Kevin Lindquist\[^{f}\], Meritxell Galindo Casas\[^{f}\], Leila M. Boustanly\[^{f}\], Colleen L. Brown\[^{f}\], Jeffrey Chabot\[^{f}\], Bruce Gomes\[^{f}\], Pamela Garzone\[^{f}\], Andrea Rossi\[^{f}\], Pavel Strop\[^{f}\], Dave Shelton\[^{f}\], Jaume Pons\[^{f2}\], and Arvind Rajpal\[^{f3}\]

From 1Rinat-Pfizer Inc., South San Francisco, California 94080 and 2Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139

Background: An antagonistic anti-PCSK9 antibody exhibits target-mediated clearance, resulting in a dose-dependent PK.

Results: Engineering of an antibody with pH-sensitive binding to PCSK9 decreases target-mediated clearance, resulting in increased PK and efficacy in vivo.

Conclusion: pH-sensitive anti-PCSK9 antibodies are excellent candidates for therapeutic development.

Significance: pH-sensitive antibodies may enable less frequent or lower dosing of antibodies hampered by target-mediated clearance and high antigen load.

Target-mediated clearance and high antigen load can hamper the efficacy and dosage of many antibodies. We show for the first time that the mouse, cynomolgus, and human cross-reactive, antagonistic anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antibodies J10 and the affinity-matured and humanized J16 exhibit target-mediated clearance, resulting in dose-dependent pharmacokinetic profiles. These antibodies prevent the degradation of low density lipoprotein receptor, thus lowering serum levels of LDL-cholesterol and potently reducing serum cholesterol in mice, and selectively lower LDL-cholesterol in cynomolgus monkeys. In order to increase the pharmacokinetic and efficacy of this promising therapeutic for hypercholesterolemia, we engineered pH-sensitive binding to mouse, cynomolgus, and human PCSK9 into J16, resulting in J17. This antibody shows prolonged half-life and increased duration of cholesterol lowering in two species in vivo by binding to endogenous PCSK9 in mice and cynomolgus monkeys, respectively. The proposed mechanism of this pH-sensitive antibody is that it binds with high affinity to PCSK9 in the plasma at pH 7.4, whereas the antibody-antigen complex dissociates at the endosomal pH of 5.5–6.0 in order to escape from target-mediated degradation. Additionally, this enables the antibody to bind to another PCSK9 and therefore increase the antigen-binding cycles. Furthermore, we show that this effect is dependent on the neonatal Fc receptor, which rescues the dissociated antibody in the endosome from degradation. Engineered pH-sensitive antibodies may enable less frequent or lower dosing of antibodies hampered by target-mediated clearance and high antigen load.

Therapeutic antibodies represent the fastest growing class of therapeutics in the pharmaceutical marketplace (1). Improving efficacy of antibodies through engineering has mainly concentrated on the Fc portion for increased half-life (2, 3) and effector function (4) and on the variable region for improved affinity. Still, several antibodies have to be dosed at high frequency or high dose in order to obtain therapeutic efficacy, often based on the high synthesis rates and/or antigen-mediated degradation of the antibody (e.g. C5, IgE, and interleukin 6 receptor (IL6R)\[^{4}\]). Antibodies with pH-dependent binding to the antigen could improve the efficacy when the antibody binds tightly to the antigen in the plasma (pH 7.4), and the antibody-antigen complex would dissociate in the acidic endosome. This would allow the antibody to undergo further binding cycles and may mitigate target-mediated degradation by dissociation of the antigen-antibody complex in the acidic endosome. We applied this method to an anti-PCSK9 (proprotein convertase subtilisin kexin type 9) antibody.

PCSK9 has been implicated as a major regulator of plasma LDL-C (5) and has emerged as a promising target for prevention and treatment of coronary heart disease. Human genetic studies identified gain-of-function mutations, which were associated with elevated serum levels of LDL-C and premature incidences of coronary heart disease, whereas loss-of-function mutations were associated with low LDL-C and reduced risk of coronary heart disease (6–9). In humans, the complete loss of PCSK9 results in low serum LDL-C of <20 mg/dl in otherwise healthy subjects (10, 11).

This article contains supplemental Figs. S1–S3, Tables S1–S4, Methods, and references.

1 Both authors contributed equally to this work.
2 To whom correspondence may be addressed: Rina-T-Pfizer Inc., 230 E. Grand Ave., South San Francisco, CA 94080. E-mail: jaume.pons@pfizer.com.
3 To whom correspondence may be addressed: Rina-T-Pfizer Inc., 230 E. Grand Ave., South San Francisco, CA 94080. E-mail: arvind.rajpal@pfizer.com.

\[^{f}\] The abbreviations used are: IL6R, interleukin 6 receptor; LDL-C, LDL-cholesterol; PK, pharmacokinetics; LDLR, low density lipoprotein receptor; FcRn, neonatal Fc receptor; PD, pharmacodynamics; CDR, complementarity-determining region; FcYR, FcY receptor.
PCSK9 belongs to the subtilisin family of serine proteases and is composed of an N-terminal prodomain, a subtilisin-like catalytic domain, and a C-terminal cysteine/histidine-rich domain. Highly expressed in the liver and intestine, PCSK9 is secreted after the autocatalytic cleavage of the prodomain, which remains non-covalently associated with the catalytic domain (12, 13). The catalytic domain of PCSK9 binds to the epidermal growth factor-like repeat A domain of LDLR with higher affinity in the endosomal pH of ~5.5–6.0 than in plasma at 7.4 (14). Although the C-terminal domain does not bind to LDLR, it has been proposed to be involved in the internalization of the LDLR-PCSK9 complex (15–17). Both functionalities of PCSK9 are required for targeting the LDLR-PCSK9 complex for lysosomal degradation and lowering LDL-C, which is in agreement with mutations in both domains linked to loss and gain of function (5).

Various therapeutic approaches for inhibiting PCSK9 have been reported, including gene silencing by siRNA or antisense oligonucleotides and disruption of the PCSK9-LDLR interaction by antibodies (18). Two monoclonal antibodies with LDL-C-lowering activity in mice and non-human primates (19, 20) were reported to have unexplained short half-lives of ~2.5 (19) and 3.2 days (20) in non-human primates at 3 mg/kg. We have reported antibodies J10 and J16, which reduced serum cholesterol in mice and monkey (21). Here we show that these antibodies exhibit a dose-dependent half-life and that this increased in vivo clearance was PCSK9-dependent. To enhance the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the antibody, we engineered pH-sensitive binding to PCSK9 (antibody J17) by introducing histidines into CDR residues of the antibody, we engineered pH-sensitive binding to the pharmacokinetic (PK) and pharmacodynamic (PD) proper-

**EXPERIMENTAL PROCEDURES**

**Proteins and Antibodies**—Recombinant human, mouse, and cynomolgus PCSK9 proteins, antibody J10 and J16 were produced and made as previously described (21). J17 was obtained by combining three histidine mutations, which were identified by a histidine-scanning mutagenesis in all CDR positions of J16. J10, J16, and J17 Concentration Measurement in Mouse Serum—Mouse sera were collected at the indicated time points. NUNC Maxisorp 96-well plates (Invitrogen) were coated with recombinant mouse PCSK9 at 5 μg/ml in PBS and incubated overnight at 4 °C. Plates were washed then blocked for 1 h at room temperature in 3% BSA in PBS at 300 μl/well. J10, J16, or J17 antibody standards were prepared in dilution buffer (0.5% BSA, 0.05% Tween 20 in PBS), with the starting concentration of 0.5 μg/ml. Serum samples were diluted at 1:500 to 1:20,000 in dilution buffer. Samples and standards were incubated in the blocked plate for 1 h at room temperature. Plates were washed, 100 μl of anti-mouse IgG (H+L) HRP (Jackson Immuno-Research, catalog no. 715-035-150) (1:5,000 dilution in PBS, 0.5% BSA) was added to each well, and plates were incubated at room temperature for 1 h. Plates were washed and developed using SUREBLUE TMB 1-C SUBSTRATE solution (VWR, catalog no. 95059-284) following the manufacturer’s instructions and read on a Molecular Devices plate reader at 450 nm. Data were analyzed using SoftMaxPro4.8, Microsoft Excel, and GraphPad Prism.

**Mouse Studies**—All mouse studies were conducted in accordance with the Institutional Animal Care and Use Committee at Pfizer Inc. Male C57BL/6 mice were purchased from Charles River Laboratories; FCRN−/− mice and PCSK9−/− mice (12, 25) were licensed and purchased from Jackson Laboratories. Mice were bred at the facility or acclimated to the facility for 2 weeks prior to the start of experiments. Animals were 6–10 weeks of age at the start of each experiment. Animals were housed conventionally under ambient conditions, with free access to water and standard rodent chow.

**Monkey Studies**—The dose response for J16 in cynomolgus monkeys was previously reported (21). The J16 and J17 comparison study was done similarly, using a total of eight male adult cynomolgus macaque (Macaca fascicularis). All animal maintenance and handling is in accordance with the Institutional Animal Care and Use Committee of the Association for Assessment and Accreditation of Laboratory Animal Care International accredited facility.

**Lipid Analysis of Serum and Plasma Samples**—Serum and plasma samples were analyzed for lipid measurements (total cholesterol, HDL-cholesterol, LDL-C, triglyceride) using Ace Alera clinical chemistry System (Alfa Wassermann). Results of lipid measurements were analyzed and graphed using GraphPad Prism software.

**Binding Affinities**—Affinity measurement of mouse, cynomolgus, and human PCSK9 at pH 6.0 and 7.4 at 37 °C were measured by Biacore T200 (GE Healthcare). The running buffers were 10 mM sodium phosphate, 150 mM NaCl, 0.05% Tween 20 (at pH 6 or 7.4). The sensor chip was an anti-human Fc surface (on a Biacore CM4 chip blocked with ethylenedia-

---

**Increasing PK and PD in Vivo by a pH-sensitive Antibody**
secondary antibodies. We followed a similar protocol to assess PCSK9 trafficking, except that PCSK9 was labeled with Alexa-488 using an Invitrogen protein labeling kit. Cells were imaged using a Leica TCS SPE laser-scanning confocal microscope with a ×63, 1.3 numerical aperture oil objective (Leica Microsystems, Mannheim, Germany). Images were collected using a 0.5-μm step size and analyzed using Leica AF software. Antibody lysosomal colocalization was calculated as the percentage of total antibody puncta that were Lamp2-positive from at least 400 puncta from each of three experiments. PCSK9-488 lysosomal colocalization was calculated as the percentage of total PCSK9-488 puncta that were Lamp2-positive. Quantifications are shown as average with S.E.; statistical significance was determined by Student’s t test. A colocalization mask was created using ImageJ software and the colocalization plugin (National Institutes of Health, Bethesda, MD).

RESULTS

Anti-PCSK9 Antibody J16 Shows Dose-dependent Half-life in Non-human Primates—We have previously reported that a humanized and affinity-matured anti-PCSK9 antibody with IgG2A heavy chain and κ light chain, J16, selectively and dose-depending lowered LDL-C in cynomolgus monkeys. This antibody contains an IgG2 subclass variant with minimal FcγR binding (21). To further study the PK of J16, we measured total plasma antibody concentrations in monkeys treated with a single bolus intravenous injection of 0.1, 1.0, 3.0, 10.0, and 100.0 mg/kg J16. The estimated half-life during the β-elimination phase was 0.7 days at a single dose of 0.1 mg/kg and increased to 1.9, 2.3, 3.5, and 5.3 days at 1.0, 3.0, 10.0, and 100.0 mg/kg, respectively (Fig. 1A and supplemental Table S1). Such dose-dependent antibody half-life is often observed with membrane-associated antigens that exhibit antigen-mediated clearance (26).

PCSK9 Mediates Enhanced Clearance of Circulating J10 in Mice—To explore the possibility that PCSK9 can enhance the elimination of an anti-PCSK9 antibody, we studied the PK of J10, the precursor of J16, with a mouse IgG1, in wild type and PCSK9-knockout mice (12). After a single bolus intravenous injection of 10 mg/kg J10 and an isotype control, the half-life of the β-phase for J10 (3.5 days) was significantly shorter than that of the isotype control (7.4 days) in wild type mice, whereas the half-lives of the two antibodies were similar in PCSK9-knockout mice (6.1 and 7.1 days, respectively) (Fig. 1, B and C, and supplemental Table S2).

Generation of Antibody with pH-sensitive Binding to PCSK9—To avoid PCSK9-mediated shortening of antibody half-life, we aimed to engineer an antibody that has pH-sensitive binding to PCSK9. It should have high affinity to PCSK9 at the neutral pH encountered in plasma to be effective in antigen binding and low affinity to PCSK9 at the low pH of the endosome to enhance antibody dissociation from PCSK9 and thus potentially escape PCSK9-mediated degradation. By histidine scanning of all the residues in the CDRs in J16, and through combination of effective mutations, we generated an antibody, J17, that exhibits a 3.8-, 2.6-, and 9.2-fold lower binding affinity at pH 6 compared with pH 7.4 for mouse, cynomologus, and human PCSK9, respectively (Table 1). Most of this pH-dependent effect comes from the difference in the rate of dissociation of the complex (kd) (supplemental Fig. S1). J17 contained histidine substitutions in CDR1 (S30H) and CDR2 (S50H) of the light chain and CDR1 (S30H) and CDR2 (S52H) of the heavy chain. Modeling suggests that His-30 in CDR1 interacts with PCSK9 residue Asp-374PCSK9, which has been shown to be partially responsible for the pH dependence of the LDLR-PCSK9 interaction (14) (supplemental Fig. S2 and supplemental Methods). Whereas LDLR binds more tightly to PCSK9 at low pH, J17 shows the opposite pH dependence and binds more tightly to PCSK9 at neutral pH. These data suggest that opposing pH dependencies can be achieved at the same interaction site, allowing the local environment to determine the direction of the pH effect.

J17 Shows Improved Serum Half-life and Extends Cholesterol Lowering in Mice and Non-human Primates—To facilitate in vivo studies, we grafted the J17 variable region onto mouse IgG1 for rodent studies and onto the human IgG2A framework for non-human primate studies. The effect of J17-mlgG1 com-

FIGURE 1. Serum antibody concentrations after J16 or J10 treatment. A, total plasma J16 antibody concentration in cynomolgus monkey after a single dose of 0.1, 1.0, 3.0, 10.0, and 100.0 mg/kg J16 over time. Results are expressed as mean ± S.E., n = 4/group. B and C, total serum J10 (circles) and an isotype control (squares) antibody concentration in wild type (B) and PCSK9-knockout (C) mice after a single dose of 10 mg/kg antibodies over time. Antibodies were dosed as a bolus intravenous injection on day 0. Results are expressed as mean ± S.E. (error bars), n = 8–9/group.
pared with J10 was studied in wild type mice at 1, 3, and 10 mg/kg doses. Antibody concentrations were monitored over 75 days. At 10 mg/kg, the β-elimination half-life for J17 was extended to 14.4 days, compared with 2.9 days for J10 (Fig. 2A and supplemental Table S3). At 1 and 3 mg/kg, the J10 antibody concentrations were below the assay’s lower limit of detection before reaching the β-phase, whereas the half-lives for J17 were 13.7 and 12.9 days, respectively. These data suggest that the half-life of J17 is not only extended at all doses when compared with J10; its half-life is no longer dose-dependent during the timeframe of these experiments. Furthermore, the half-life of the β-phase for J17 was similar to that of the isotype control antibody at 10 mg/kg (9.4 days), suggesting that PCSK9-mediated degradation of J17 in circulation was significantly reduced (Fig. 2A and supplemental Table S3). To confirm the prolonged PK of J17-hlgG2ΔA in non-human primates, 1.5 mg/kg J16 and J17 were injected intravenously into cynomolgus monkeys. J17 has an estimated half-life of 7.4 days compared with 0.9 days for J10 (Fig. 2B and supplemental Table S4). To ensure that the observed differences were not based on different affinities to FcRn, we confirmed similar affinities of J16 and J17 with cynomolgus FcRn by surface plasmon resonance (supplemental Fig. S3).

To explore whether the improved PK also results in improved duration of efficacy, total cholesterol levels were measured in mice treated with 1, 3, or 10 mg/kg J10 or J17-hlgG1 over 75 days. The animals dosed with isotype control antibody display total cholesterol levels between 90 and 100 mg/dl throughout the study. The animals dosed with 1 mg/kg J10 show minimal change; 3 and 10 mg/kg doses of J10 lower total cholesterol to 75 and 65 mg/dl at day 4, and cholesterol levels recover to base line at day 20 and 25, respectively (Fig. 2C). The 1, 3, and 10 mg/kg doses of J17 lower total cholesterol to 78, 75, and 65 mg/dl and do not recover to base-line levels until day 75 (Fig. 2C). Compared with J10, J17 had an equivalent magnitude of cholesterol lowering, with extended duration at all doses tested in mice. To confirm the enhanced cholesterol-lowering effect of J17 in non-human primates, a single intravenous dose of 1.5 mg/kg J16 or J17 was injected in cynomolgus monkeys. Both J16 and J17 treatment lower the LDL-C concentration by ~50% at peak efficacy. LDL-C in J16-treated animals starts to recover by day 4 and returns to base line by day 10, whereas LDL-C in J17-treated animals starts to recover only around day 10 and returns to base line at day 30 (Fig. 2D).

**J17 Shows Reduced PCSK9-dependent Lysosomal Accumulation Compared with J16**—We next looked at cellular trafficking of J10 and J17 in a hepatic cell line in an effort to mechanistically understand whether the increased half-life of J17 is due to reduced lysosomal trafficking and degradation. To address this, we incubated HepG2 cells with PCSK9 in the presence of J10, J17, or an isotype control and looked for lysosomal co-localization of the antibodies by laser-scanning confocal microscopy. We observed that both J10 and J17, but not the isotype control, are internalized when in the presence of PCSK9 and, interestingly, that J10 is trafficked to lysosomes more effectively than J17 (Fig. 3, A and B). Employing similar techniques, we determined that PCSK9 is trafficked to the lysosomes as efficiently in the presence of J10 and J17 as in the presence of the isotype control (Fig. 3B). These results suggest that J17 is differentially trafficked away from lysosomes independently of PCSK9, thus rescuing J17 from PCSK9-mediated lysosomal degradation.

**PCSK9 Has Minimal Effect on J17 Serum Half-life**—To further demonstrate that PCSK9 accelerates J10 clearance and that this effect is mitigated by J17, we studied the effect of the addition of exogenous recombinant human PCSK9 (hhuPCSK9) after dosing antibodies into PCSK9−/− mice. A dose of 10 mg/kg of J10, J17, and an isotype control was injected by the intraperitoneal route into PCSK9−/− mice. The three antibodies have similar serum concentrations throughout the first 14 days postinjection. On day 15 of the experiment, 3 mg/kg recombinant hhuPCSK9 was administered intravenously. The J10 antibody concentration dropped to 24% of the previous day’s value (day 14) 1 h after the injection of hhuPCSK9, whereas the isotype control and J17 antibody concentration only dropped to 88 and 81%, respectively, during the same period (Fig. 4A). These results suggest that the introduced pH sensitivity of J17 protects the antibody from PCSK9-mediated degradation.

**Prolonged Serum Half-life of J17 Is FcRn-dependent**—FcRn extends antibody half-life in vivo by protecting IgG from degradation because the serum half-life of IgG is greatly reduced in Fcrn−/− mice (25). To evaluate the role of FcRn in the PCSK9-mediated degradation of J10 and rescue of J17, we injected
intravenously 10 mg/kg J10, J17, and an isotype control into FCRN−/− mice. As expected, the antibodies showed faster clearance (Fig. 4B) compared with wild type mice (Figs. 1B and 2A). J10 and J17 both have half-lives of 0.7 days, shorter than that of the isotype control (1.1 days) (Fig. 4B). In comparison, the half-life for J17 (14.4 days) was comparable with that of the isotype control (9.4 days) and significantly longer than that of J10 (2.9 days) in wild type mice (Fig. 2A and supplemental Table S3). Together these results suggest that the rescue of J17 from PCSK9-mediated degradation occurs through J17 binding to FcRn in acidic endosomal vesicles and subsequent release to the circulation due to the increase in pH at the cell surface.

DISCUSSION

The two main mechanisms for active elimination of IgG are a target-independent clearance pathway mediated by interaction between the Fc region on the antibody and the Fc receptors (FcRn and FcγR) and, second, a target-mediated clearance pathway due to specific interaction between the Fab region of the antibody and its pharmacological target (27, 28). Few soluble antigens undergo target-mediated elimination and often have dose-independent clearance rates for the soluble antibody-antigen complexes (29), which concomitantly lead to increased half-life of the antigen in complex with the antibody (30). An exception can be the elimination of the immune complexes through FcγR-mediated phagocytosis (26, 30, 31), when two or more antibodies bind simultaneously to one antigen. Target-mediated clearance results in dose-dependent elimination rates at different concentrations based on the saturable binding to the antigen. Antibodies targeting membrane-bound receptors often display increased clearance by target-mediated degradation (29), where after binding to the receptor and receptor-mediated endocytosis, the receptor-antibody complex can be degraded.

Given the assumed 1:1 stoichiometry per binding site of J10 and J16 and the minimal FcγR binding of the IgG2A subclass variant, we do not expect the formation of large complexes yielding a rapid clearance. However, despite this, we clearly observe dose-dependent degradation of J16 (Fig. 1A). We con-
In the present paper, we engineered an anti-PCSK9 antibody to have pH-sensitive antigen binding in an effort to enhance exposure and reduced target-mediated clearance. Our antibody is cross-reactive to mouse, cynomolgus, and human PCSK9, allowing the measurement of PK and PD parameters in multiple in vivo models. As a PD and efficacy end point, we were able to measure the cholesterol-lowering effect of the antibodies in mice and monkeys. We show that in wild-type mice J17 is able to abrogate target-mediated degradation, as seen by comparing its half-life with an isotype control (Fig. 2A). We were able to demonstrate this effect in PCSK9−/− mice after injecting human PCSK9 and showing that only the J10 serum concentration was reduced compared with J17 and the isotype control antibody (Fig. 3C). The total cholesterol levels of wild type mice injected with 10 mg/kg J10 and J17 were reduced to around 50% of the base-line level, with a 2.8-fold increase in the duration of maximum efficacy by using J17. We also showed improved PK and efficacy in monkeys at a 1.5 mg/kg dose, which results in a 2.5-fold improvement of the duration of the maximum effect and a 3-fold improvement of the recovery to base-line cholesterol levels using J17. These results suggest that the engineered pH sensitivity leads to increased cycles of antigen binding, internalization, dissociation, antigen degradation, antibody recycling to the plasma, and binding of fresh antigen. Our data suggest that J17 dissociates from PCSK9 in the endosome and minimizes target-mediated degradation, compared with the parental antibody J10. Consistent with this, we saw decreased localization of J17 in the lysosome of HepG2 cells when co-incubated with PCSK9 (Fig. 3, A and B). We hypothesized that this rescue can only occur if FcRn is also present in the same cell to recycle the antibody. In order to confirm this hypothesis, we measured the half-life of J10, J17, and an isotype control antibody in FCRN−/− mice (25), where we find that the difference in PK between J10 and J17 is minimized (Fig. 4B), suggesting the crucial role of FcRn in the rescue of J17 from PCSK9-mediated degradation. It is also interesting to note that although J17 showed a half-life comparable with that of the isotype control in wild type animals (Fig. 2A), it shows faster elimination in FCRN−/− animals compared with the control antibody (Fig. 4B). This finding suggests that there may be other factors affecting J10 and J17 elimination in addition to PCSK9 and FcRn.

Recently, Igawa et al. (22) generated a pH-dependent anti-human IL6R antibody by histidine scanning of the CDers in tocolizumab. They measured the PK and PD in transgenic human IL6R animals by injecting human IL6 due to lack of rodent cross-reactivity in tocolizumab. These studies were unable to dissect the role of IL6 and IL6R synthesis in vivo and were further complicated by human IL6 binding to mouse and human IL6R. Despite these complications, the pH-sensitive antibody showed decreased clearance and increased inhibition of downstream serum amyloid A. They also demonstrated improved PK and PD for a pH-sensitive antibody containing enhanced FcRn binding mutations after injection of human IL6 daily and measuring the PD marker C-reactive protein in monkeys. Although the data were promising, the study combined mechanisms for reducing target-independent and target-mediated elimination simultaneously, confounding analysis of individual components.

In the past, methods for increasing the half-life of antibodies have mainly focused on increasing the affinity of Fc to FcRn (2, 3) in order to decrease target-independent clearance. In the case of proteins other than antibodies, two groups have shown pH-dependent binding of engineered cytokines with increased dissociation in the endosomes, which correlates with increased recycling in vitro (24, 32). Histidine has a pKₐ of ~6 and is often found at the interfaces of proteins that interact with differential affinities in the plasma and endosome, such as FcRn (33) and human epidermal growth factor (32). Sakar et al. (24) introduced histidines using a rational design on the granulocyte colony-stimulating factor region interacting with its cognate receptor. They maintained affinity at plasma pH of 7.4, whereas the affinity was decreased at endosomal pH of 5.5–6.0 by putative protonation of these histidines. This led to increased recycling of the dissociated ligand and receptor to the cell surface, where they could bind to each other and signal again. Enhanced PK and PD in vitro were obtained by reducing degradation and allowing for repeated binding.

In the present paper, we engineered an anti-PCSK9 antibody to have pH-sensitive antigen binding in an effort to enhance exposure and reduced target-mediated clearance. Our antibody is cross-reactive to mouse, cynomolgus, and human PCSK9, allowing the measurement of PK and PD parameters in multiple in vivo models. As a PD and efficacy end point, we were able to measure the cholesterol-lowering effect of the antibodies in mice and monkeys. We show that in wild-type mice J17 is able to abrogate target-mediated degradation, as seen by comparing its half-life with an isotype control (Fig. 2A). We were able to demonstrate this effect in PCSK9−/− mice after injecting human PCSK9 and showing that only the J10 serum concentration was reduced compared with J17 and the isotype control antibody (Fig. 3C). The total cholesterol levels of wild type mice injected with 10 mg/kg J10 and J17 were reduced to around 50% of the base-line level, with a 2.8-fold increase in the duration of maximum efficacy by using J17. We also showed improved PK and efficacy in monkeys at a 1.5 mg/kg dose, which results in a 2.5-fold improvement of the duration of the maximum effect and a 3-fold improvement of the recovery to base-line cholesterol levels using J17. These results suggest that the engineered pH sensitivity leads to increased cycles of antigen binding, internalization, dissociation, antigen degradation, antibody recycling to the plasma, and binding of fresh antigen. Our data suggest that J17 dissociates from PCSK9 in the endosome and minimizes target-mediated degradation, compared with the parental antibody J10. Consistent with this, we saw decreased localization of J17 in the lysosome of HepG2 cells when co-incubated with PCSK9 (Fig. 3, A and B). We hypothesized that this rescue can only occur if FcRn is also present in the same cell to recycle the antibody. In order to confirm this hypothesis, we measured the half-life of J10, J17, and an isotype control antibody in FCRN−/− mice (25), where we find that the difference in PK between J10 and J17 is minimized (Fig. 4B), suggesting the crucial role of FcRn in the rescue of J17 from PCSK9-mediated degradation. It is also interesting to note that although J17 showed a half-life comparable with that of the isotype control in wild type animals (Fig. 2A), it shows faster elimination in FCRN−/− animals compared with the control antibody (Fig. 4B). This finding suggests that there may be other factors affecting J10 and J17 elimination in addition to PCSK9 and FcRn.

Recently, Igawa et al. (22) generated a pH-dependent anti-human IL6R antibody by histidine scanning of the CDRs in tocolizumab. They measured the PK and PD in transgenic human IL6R animals by injecting human IL6 due to lack of rodent cross-reactivity in tocolizumab. These studies were unable to dissect the role of IL6 and IL6R synthesis in vivo and were further complicated by human IL6 binding to mouse and human IL6R. Despite these complications, the pH-sensitive antibody showed decreased clearance and increased inhibition of downstream serum amyloid A. They also demonstrated improved PK and PD for a pH-sensitive antibody containing enhanced FcRn binding mutations after injection of human IL6 daily and measuring the PD marker C-reactive protein in monkeys. Although the data were promising, the study combined mechanisms for reducing target-independent and target-mediated elimination simultaneously, confounding analysis of individual components.

In the present paper, we engineered an anti-PCSK9 antibody to have pH-sensitive antigen binding in an effort to enhance exposure and reduced target-mediated clearance. Our antibody is cross-reactive to mouse, cynomolgus, and human PCSK9, allowing the measurement of PK and PD parameters in multiple in vivo models. As a PD and efficacy end point, we were able to measure the cholesterol-lowering effect of the antibodies in mice and monkeys. We show that in wild-type mice J17 is able to abrogate target-mediated degradation, as seen by comparing its half-life with an isotype control (Fig. 2A). We were able to demonstrate this effect in PCSK9−/− mice after injecting human PCSK9 and showing that only the J10 serum concentration was reduced compared with J17 and the isotype control antibody (Fig. 3C). The total cholesterol levels of wild type mice injected with 10 mg/kg J10 and J17 were reduced to around 50% of the base-line level, with a 2.8-fold increase in the duration of maximum efficacy by using J17. We also showed improved PK and efficacy in monkeys at a 1.5 mg/kg dose, which results in a 2.5-fold improvement of the duration of the maximum effect and a 3-fold improvement of the recovery to base-line cholesterol levels using J17. These results suggest that the engineered pH sensitivity leads to increased cycles of antigen binding, internalization, dissociation, antigen degradation, antibody recycling to the plasma, and binding of fresh antigen. Our data suggest that J17 dissociates from PCSK9 in the endosome and minimizes target-mediated degradation, compared with the parental antibody J10. Consistent with this, we saw decreased localization of J17 in the lysosome of HepG2 cells when co-incubated with PCSK9 (Fig. 3, A and B). We hypothesized that this rescue can only occur if FcRn is also present in the same cell to recycle the antibody. In order to confirm this hypothesis, we measured the half-life of J10, J17, and an isotype control antibody in FCRN−/− mice (25), where we find that the difference in PK between J10 and J17 is minimized (Fig. 4B), suggesting the crucial role of FcRn in the rescue of J17 from PCSK9-mediated degradation. It is also interesting to note that although J17 showed a half-life comparable with that of the isotype control in wild type animals (Fig. 2A), it shows faster elimination in FCRN−/− animals compared with the control antibody (Fig. 4B). This finding suggests that there may be other factors affecting J10 and J17 elimination in addition to PCSK9 and FcRn.
In the past, improving PK of antibodies was mainly obtained by engineering the Fc for increased affinity to FcRn, which may be less effective in addressing target-mediated degradation. The method presented here increases exposure by decreasing or eliminating target-mediated degradation and has two potential beneficial effects for improving PD. The first is to prevent the incomplete usage of antibodies bound to one antigen and subsequently degraded, and the second is the recycling of free antibody, resulting in increased antigen-binding cycles. In general, increasing the efficacy of antibodies has conventionally been accomplished by improving affinity, especially for soluble antigens. In contrast, generating pH-sensitive antibodies is a balance of high affinity at pH 7.4, resulting in effective target occupancy, and fast dissociation kinetics ($k_d$) at pH 6.0, to facilitate antigen release in the endosome, resulting in enhanced PK and efficacy (22, 24). The applicability of this methodology has been shown for IL6R and PCSK9 but should be considered with care for new targets. High antigen concentration and rapid target-mediated degradation are situations where a pH-sensitive antibody may be beneficial; however, it is not clear how these two characteristics interplay in defining ideal targets.

Acknowledgments—We thank S. Michael Chin, Amber Pham, Ishita Barman, and Charles Appah for expressing and purifying proteins; Dan Malashock, Mayumi Pierce, and Yasmina Abidiche for providing Biosensor support; Kapi Kapil Mayawala and Jake Glanville for modeling; and Wenwu Zhai for initiating the project.

REFERENCES

1. Nelson, A. L., Dhimolea, E., and Reichert, J. M. (2010) Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug. Discov., 9, 767–774
2. Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starosvaskin, M. A., and Lowman, H. B. (2009) Engineering human IgG1 affinity to human neonatal Fc receptor. Impact of affinity improvement on pharmacokinetics in primates. J. Immunol., 182, 7663–7671
3. Zalesky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W., Sproule, T. J., Lazar, G. A., Roopenian, D. C., and Desjarlais, J. R. (2010) Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol., 28, 157–159
4. Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., Vielmetter, J., Carmichael, D. F., Hayes, R. J., and Dahiyat, B. I. (2006) Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A., 103, 4005–4010
5. Lambert, G., Charlton, F., Rye, K. A., and Piper, D. E. (2009) Molecular basis of PCSK9 function. Atherosclerosis, 203, 1–7
6. Abifadel, M., Varret, M., Rabés, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Leabman, M., Cruaud, C., Benjannet, S., Hattori, K. (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. J. Biol. Chem., 285, 12882–12891
7. Zhang, D. W., Garuti, R., Tang, W. J., Cohen, J. C., and Hobbs, H. H. (2008) Structural requirements for PCSK9-mediated degradation of the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A., 105, 13045–13050
8. Abifadel, M., Pakradouni, J., Collin, M., Samson-Bouma, M. E., Varret, M., Rabés, J. P., and Boileau, C. (2010) Strategies for proprotein convertase subtilisin/kexin 9 modulation: A perspective on recent patents. Expert. Opin. Ther. Pat., 20, 1547–1571
9. Chan, J. C., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., Di, Y., Shetterly, S., Arimura, Z., Salomonis, H., Romanow, W. G., Thibaut, S. T., Zhang, R., Cao, P., Yang, X. P., Tu, Y., Lu, M., Retter, M. W., Kwon, G. H., Heine, K., Pan, O., Tsai, M. S., Kuchle, B., Yang, E. Z., Zhou, L., Lee, K. J., Darius, M., Sheng, J., Wang, Y., Shen, W. D., Yeh, W. C., Emery, M., Walker, N. P., Shon, B., Schwarcz, M., and Jackson, S. S. (2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. U.S.A., 106, 9820–9825
10. Ni, Y. G., Marais, A. D., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., Santoro, J. C., Ehrhardt, A., Lewis, D., Fisher, T. S., Ha, N., Jumoluh, L., Wood, D. D., Hammond, H. A., Wisniewski, D. D., Volpari, C., Noto, A., Lo Surdo, P., Hubbard, B., Carfi, A., and Sitlani, A. (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and reduces low density lipoprotein uptake. J. Biol. Chem., 285, 12882–12891
11. Chambers, H. M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2009) PCSK9. A convertase subtilisin/kexin type 9 modulator. J. Biochem. Pharmacol., 79, 718–732
12. Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M., and Burnett, J. R. (2007) The angiopoietin-1 receptor as a target for dyslipidaemia. Atherosclerosis, 193, 445–448
13. Bottomley, M. J., Cirillo, A., Olszynko, T., Rutter, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Lo Surdo, P., Calzetta, A., Noto, A., Barbashovitch, J., Teper, A., Talamo, F. De Francesco, R., Sparrow, C. P., Sitlani, A., and Carfi, A. (2009) Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J. Biol. Chem., 284, 1313–1323
14. Hayes, R. J., and Dahiyat, B. I. (2006) Engineered antibody Fc variants with increased affinity to FcRn, which may be beneficial; however, it is not clear how these two characteristics interplay in defining ideal targets.
23. Murtaugh, M. L., Fanning, S. W., Sharma, T. M., Terry, A. M., and Horn, J. R. (2011) A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. Protein Sci. 20, 1619–1631
24. Sarkar, C. A., Lowenhaupt, K., Horan, T., Boone, T. C., Tidor, B., and Lauffenburger, D. A. (2002) Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching”. Nat. Biotechnol. 20, 908–913
25. Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S., Avanessian, L., Choi, E. Y., Shaffer, D. J., Eden, P. A., and Anderson, C. L. (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Immunol. 170, 3528–3533
26. Tabrizi, M., Bornstein, G. G., and Suria, H. (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 12, 33–43
27. Dirks, N. L., and Meibohm, B. (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 633–659
28. Wang, W., Wang, E. Q., and Balthasar, J. P. (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548–558
29. Tabrizi, M. A., Tseng, C. M., and Roskos, L. K. (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug. Discov. Today 11, 81–88
30. Rehaender, B. N., and Cho, M. J. (1998) Antibodies as carrier proteins. Pharm. Res. 15, 1652–1656
31. Hayashi, N., Tsukamoto, Y., Sallas, W. M., and Lowe, P. J. (2007) Br. J. Clin. Pharmacol. 63, 548–561
32. Maeda, K., Kato, Y., and Sugiyama, Y. (2002) pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. J. Control Release 82, 71–82
33. Raghavan, M., Bonagura, V. R., Morrison, S. L., and Bjorkman, P. J. (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34, 14649–14657